特鲁希略-秘鲁 2023 年非 COVID-19 患者和有或无代谢综合征的 COVID-19 后患者的心脏标志物。

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2024-11-20 eCollection Date: 2024-01-01 DOI:10.2147/DMSO.S476971

Jorge Luis Díaz-Ortega, Nelida Milly Otiniano, Irma Luz Yupari-Azabache, Juan M Alva Sevilla

{"title":"特鲁希略-秘鲁 2023 年非 COVID-19 患者和有或无代谢综合征的 COVID-19 后患者的心脏标志物。","authors":"Jorge Luis Díaz-Ortega, Nelida Milly Otiniano, Irma Luz Yupari-Azabache, Juan M Alva Sevilla","doi":"10.2147/DMSO.S476971","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in apparently non-COVID-19 (COVID-19-) and post-COVID-19 (COVID-19+) persons with metabolic syndrome (MetS+) and without metabolic syndrome (MetS-).Methods: The descriptive correlational study was carried out in 275 inhabitants of the city of Trujillo in 2023. Cardiac markers were determined by time-resolved immunofluorescence.Results: It was determined that 58.2% of the participants presented COVID-19 and 46.5% presented a diagnosis of MetS according to the harmonized ATP III criteria. Levels of cTnI greater than 0.05 ng/mL were found in low percentages in the COVID-19-/MetS-, COVID-19-/MetS+, and COVID-19+/MetS- groups at 0.7% each, and in the COVID-19+/SM+ group, it was 0.4%. NT-proBNP concentrations higher than 125 pg/mL were found in 2.9% of participants, of which 1.1% were in the COVID-19+/MetS+ group, a slightly higher proportion compared to the other groups.Conclusion: The proportion of individuals with normal or elevated cTnI and NT-ProBNP levels does not differ significantly in both healthy individuals, with MetS only, and those with mild Post COVID-19 with or without MetS; however, longitudinal studies are required to detect possible myocardial events in either group for adequate treatment, especially in those with COVID-19+/MetS+.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"17 ","pages":"4307-4317"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586487/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cardiac Markers in Apparently Non-COVID-19 Individuals and Post-COVID-19 Individuals with and without Metabolic Syndrome, Trujillo-Peru 2023.\",\"authors\":\"Jorge Luis Díaz-Ortega, Nelida Milly Otiniano, Irma Luz Yupari-Azabache, Juan M Alva Sevilla\",\"doi\":\"10.2147/DMSO.S476971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To compare the levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in apparently non-COVID-19 (COVID-19-) and post-COVID-19 (COVID-19+) persons with metabolic syndrome (MetS+) and without metabolic syndrome (MetS-).Methods: The descriptive correlational study was carried out in 275 inhabitants of the city of Trujillo in 2023. Cardiac markers were determined by time-resolved immunofluorescence.Results: It was determined that 58.2% of the participants presented COVID-19 and 46.5% presented a diagnosis of MetS according to the harmonized ATP III criteria. Levels of cTnI greater than 0.05 ng/mL were found in low percentages in the COVID-19-/MetS-, COVID-19-/MetS+, and COVID-19+/MetS- groups at 0.7% each, and in the COVID-19+/SM+ group, it was 0.4%. NT-proBNP concentrations higher than 125 pg/mL were found in 2.9% of participants, of which 1.1% were in the COVID-19+/MetS+ group, a slightly higher proportion compared to the other groups.Conclusion: The proportion of individuals with normal or elevated cTnI and NT-ProBNP levels does not differ significantly in both healthy individuals, with MetS only, and those with mild Post COVID-19 with or without MetS; however, longitudinal studies are required to detect possible myocardial events in either group for adequate treatment, especially in those with COVID-19+/MetS+.\",\"PeriodicalId\":11116,\"journal\":{\"name\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"volume\":\"17 \",\"pages\":\"4307-4317\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586487/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DMSO.S476971\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S476971","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：比较患有代谢综合征（MetS+）和未患代谢综合征（MetS-）的非 COVID-19 (COVID-19-) 和 COVID-19 后 (COVID-19+) 患者的心肌肌钙蛋白 I (cTnI) 和 N 端前脑钠肽 (NT-proBNP) 水平：这项描述性相关研究是在 2023 年对特鲁希略市的 275 名居民进行的。采用时间分辨免疫荧光法测定心脏标志物：根据 ATP III 统一标准，58.2% 的参与者患有 COVID-19，46.5% 的参与者被诊断患有 MetS。在 COVID-19-/MetS-、COVID-19-/MetS+ 和 COVID-19+/MetS- 组中，cTnI 水平大于 0.05 纳克/毫升的比例较低，分别为 0.7%，而在 COVID-19+/SM+ 组中，这一比例为 0.4%。2.9%的参与者发现NT-proBNP浓度高于125 pg/mL，其中COVID-19+/MetS+组为1.1%，这一比例略高于其他组别：结论：cTnI和NT-ProBNP水平正常或升高的个体比例在仅患有MetS的健康个体和患有轻度COVID-19后遗症并伴有或不伴有MetS的个体中并无显著差异；然而，需要进行纵向研究，以检测这两组个体中可能发生的心肌事件，从而进行适当治疗，尤其是COVID-19+/MetS+患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cardiac Markers in Apparently Non-COVID-19 Individuals and Post-COVID-19 Individuals with and without Metabolic Syndrome, Trujillo-Peru 2023.

Purpose: To compare the levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in apparently non-COVID-19 (COVID-19-) and post-COVID-19 (COVID-19+) persons with metabolic syndrome (MetS+) and without metabolic syndrome (MetS-).

Methods: The descriptive correlational study was carried out in 275 inhabitants of the city of Trujillo in 2023. Cardiac markers were determined by time-resolved immunofluorescence.

Results: It was determined that 58.2% of the participants presented COVID-19 and 46.5% presented a diagnosis of MetS according to the harmonized ATP III criteria. Levels of cTnI greater than 0.05 ng/mL were found in low percentages in the COVID-19-/MetS-, COVID-19-/MetS+, and COVID-19+/MetS- groups at 0.7% each, and in the COVID-19+/SM+ group, it was 0.4%. NT-proBNP concentrations higher than 125 pg/mL were found in 2.9% of participants, of which 1.1% were in the COVID-19+/MetS+ group, a slightly higher proportion compared to the other groups.

Conclusion: The proportion of individuals with normal or elevated cTnI and NT-ProBNP levels does not differ significantly in both healthy individuals, with MetS only, and those with mild Post COVID-19 with or without MetS; however, longitudinal studies are required to detect possible myocardial events in either group for adequate treatment, especially in those with COVID-19+/MetS+.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.